Improved response by co-targeting EGFR/EGFRvIII and Src family kinases in human cancer cells

Cancer Investigation

Volumn 27, Issue 2, 2009, Pages 178-183

  Andersen, Peter ^a   Villingshøj, Mette ^a   Poulsen, Hans Skovgaard ^a   Stockhausen, Marie Thérèse ^a  

^a FINSEN LABORATORY   (Denmark)

Author keywords

AZD0530; Cancer; EGFR; EGFRvIII; Gefitinib; Src

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; N (5 CHLORO 1,3 BENZODIOXOL 4 YL) 7 [2 (4 METHYL 1 PIPERAZINYL)ETHOXY] 5 (TETRAHYDRO 2H PYRAN 4 YLOXY) 4 QUINAZOLINAMINE; PROTEIN TYROSINE KINASE;

ARTICLE; CANCER CELL; CANCER INHIBITION; CELL MIGRATION; CELL PROLIFERATION; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG SENSITIVITY; GROWTH INHIBITION; HUMAN; HUMAN CELL; MIGRATION INHIBITION; MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; WILD TYPE;

BENZODIOXOLES; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; HUMANS; NEOPLASMS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SRC-FAMILY KINASES;

EID: 60849085467     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900802570759     Document Type: Article

References (22)

1. Zandi, R.; Larsen, A.B.; Andersen, P.; Stockhausen, M.T.; Poulsen, H.S. Mechanisms for oncogenic activation of the epidermal growth factor receptor. Cell Signal 2007, 19, 2013-2023.
2. Summy, J.M.; Gallick, G.E. Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev 2003, 22, 337-358.
3. Zhu, S.; Bjorge, J.D.; Fujita, D.J. PTP1B contributes to the oncogenic properties of colon cancer cells through Src activation. Cancer Res 2007, 67, 10129-10137.
4. Hara, F.; Aoe, M.; Doihara, H.; Taira, N.; Shien, T.; Takahashi, H.; et al. Antitumor effect of gefitinib ('Iressa') on esophageal squamous cell carcinoma cell lines in vitro and in vivo. Cancer Lett 2005, 226, 37-47.
5. Small, E.J.; Fontana, J.; Tannir, N.; DiPaola, R.S.; Wilding, G.; Rubin, M.; et al. A phase II trial of gefitinib in patients with non-metastatic hormone-refractory prostate cancer. BJU Int 2007, 100, 765-769.
6. Posadas, E.M.; Liel, M.S.; Kwitkowski, V.; Minasian, L.; Godwin, A.K.; Hussain, M.M.; et al. A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer. Cancer 2007, 109, 1323-1330.
7. Stommel, J.M.; Kimmelman, A.C.; Ying, H.; Nabioullin, R.; Ponugoti, A.H.; Wiedemeyer, R.; et al. Co-activation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 2007, 318, 287-290.
8. Engelman, J.A.; Zejnullahu, K.; Mitsudomi, T.; Song, Y.; Hyland, C.; Park, J.O.; et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316, 1039-1043.
9. Hiscox, S.; Morgan, L.; Green, T.P.; Barrow, D.; Gee, J.; Nicholson, R.I. Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells. Breast Cancer Res Treat 2006, 97, 263-274.
10. Ishizawar, R.; Parsons, S.J. c-Src and cooperating partners in human cancer. Cancer Cell 2004, 6, 209-214.
11. Bromann, P.A.; Korkaya, H.; Courtneidge, S.A. The interplay between Src family kinases and receptor tyrosine kinases. Oncogene 2004, 23, 7957-7968.
12. Pedersen, M.W.; Pedersen, N.; Damstrup, L.; Villingshøj, M.; Sønder, S.U.; Rieneck, K.; et al. Analysis of the epidermal growth factor receptor specific transcriptome: effect of expression level and an activating mutation. J Cell Biochem 2005, 96, 412-427.
13. Learn, C.A.; Hartzell, T.L.; Wikstrand, C.J.; Archer, G.E.; Rich, J.N.; Friedman, A.H.; et al. Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme. Clin Cancer Res 2004, 10, 3216-3224.
14. Pedersen, M.W.; Pedersen, N.; Ottesen, L.H.; Poulsen, H.S. Differential response to gefitinib of cells expressing normal EGFR and the mutant EGFRvIII. Br J Cancer 2005, 93, 915-923.
15. Kwok, T.T.; Sutherland, R.M. Differences in EGF related radiosensitisation of human squamous carcinoma cells with high and low numbers of EGF receptors. Br J Cancer 1991, 64, 251-254.
16. Andersen, P.; Pedersen, M.W.; Woetmann, A.; Villingshoj, M.; Stockhausen, M.T.; Odum, N.; et al. EGFR induces expression of IRF-1 via STAT1 and STAT3 activation leading to growth arrest of human cancer cells. Int J Cancer 2007, 122, 342-349.
17. Kamer, A.R.; Sacks, P.G.; Vladutiu, A.; Liebow, C. EGF mediates multiple signals: dependence on the conditions. Int J Mol Med 2004, 13, 143-147.
18. Larsen, A.B.; Pedersen, M.W.; Stockhausen, M.T.; Grandal, M.V.; van Deurs, B.; Poulsen, H.S. Activation of the EGFR gene target EphA2 inhibits epidermal growth factor-induced cancer cell motility. Mol Cancer Res 2007, 5, 283-293.
19. Pedersen, M.W.; Tkach, V.; Pedersen, N.; Berezin, V.; Poulsen, H.S. Expression of a naturally occurring constitutively active variant of the epidermal growth factor receptor in mouse fibroblasts increases motility. Int J Cancer 2004, 108, 643-653.
20. Serrano, M.; Lin, A.W.; McCurrach, M.E.; Beach, D.; Lowe, S.W. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 1997, 88, 593-602.
21. Montgomery, R.B. Antagonistic and agonistic effects of quinazoline tyrosine kinase inhibitors on mutant EGF receptor function. Int J Cancer 2002, 101, 111-117.
22. Sakamoto, M.; Takamura, M.; Ino, Y.; Miura, A.; Genda, T.; Hirohashi, S. Involvement of c-Src in carcinoma cell motility and metastasis. Jpn J Cancer Res 2001, 92, 941-946.